The abstract is read at the publisher; the summary is JClub's.
In a xenograft model of human CAR T-cell therapy, inhibiting CCR1/CCR2 significantly reduced clinical CRS and inflammatory cytokines while preserving CAR T-cell antitumor efficacy.
- Why it matters: CRS is a dose-limiting toxicity, and the upstream signals that activate macrophages during CAR T-cell treatment are not fully defined.
- What they did: The study combined a xenograft CAR T-cell model with single-cell RNA sequencing and pharmacological CCR1/CCR2 blockade, and validated macrophage signatures using clinical scRNA-seq from CAR T-treated glioblastoma patients.
- The result: CAR T-cell treatment increased CRS-associated macrophages and upregulated CCR1/CCR2 with CCL3/CCL2-linked pathways; CCR1/CCR2 inhibition reduced CRS and macrophage activation without impairing CAR T-cell expansion, effector cytokines, or in vivo tumor control.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.